-
2023-508196-36-00
4
2025-05-27
Follicular lymphoma
-
2024-514937-39-00
5
2025-05-20
Dravet Syndrome
-
2024-515445-42-00
5
2025-03-24
Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast
-
2024-515530-33-00
6
2025-03-23
coronary artery disease
Aortic valve disease
Mitral valve disease
Tric
-
2024-511652-40-00
5
2025-02-05
METASTATIC CASTRATION RESISTANT PROSTATE CANCER
-
2024-520288-15-00
6
2025-01-25
Metastatic or locally advanced inoperable colorectal cancer
-
2023-508813-18-00
4
2024-12-18
Refractory Focal Onset Epilepsy
-
2023-509994-22-00
5
2024-11-15
cutaneous malignant melanoma
-
2024-517478-68-01
4
2024-11-06
Advanced Cancer
-
2024-517508-12-00
6
2024-10-24
Undergoing hysterectomy
-
2022-500596-32-00
4
2024-10-01
Aneyrysmal subarachnoid hemorrhage needing ventilatory care in intensi
-
2023-508811-21-00
10
2024-09-25
Refractory Focal Onset Epilepsy
-
2023-510415-19-00
4
2024-08-28
Acute Myeloid Leukemia
-
2023-507486-26-00
1
2024-08-20
Advanced metastatic castration-resistant prostate cancer with prostate
-
2024-516495-15-00
6
2024-08-12
labour
-
2023-504962-52-00
5
2024-07-10
Triple negative breast cancer.
-
2023-507407-59-00
5
2024-07-04
Chronic Obstructive Pulmonary Disease (COPD)
-
2023-507914-28-00
10
2024-06-19
Platinum-resistant, high-grade serous ovarian cancer (OVC),high-grade
-
2023-507871-23-00
5
2024-05-27
Relapsed/Refractory Multiple Myeloma
-
2023-504899-25-00
5
2024-04-04
Metastatic castration resistant prostate cancer
-
2022-502282-24-00
5
2024-02-14
Primary generalized tonic-clonic seizures
-
2023-503327-26-00
5
2024-01-31
Sjogren's syndrome
-
2022-502980-39-00
5
2024-01-25
Estrogen receptor (ER)-positive, HER2-negative advanced breast cancer
-
2023-504340-34-01
6
2024-01-11
Coronary artery disease